Critical appraisal of epigenetic regulation of galectins in cancer.
Cancer
Epigenetics
Galectins
Methylation
miRNA
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
02
07
2021
accepted:
03
10
2021
pubmed:
16
10
2021
medline:
8
1
2022
entrez:
15
10
2021
Statut:
ppublish
Résumé
Galectins are defined as the glycan-binding protein containing either one or two carbohydrate-binding domains and participate in various biological functions such as developmental processes, vascularisation programs, cell migration, and immune-regulation and apoptosis. Galectins are also linked to many diseases, including cancer. They are widely spread in extracellular and intracellular spaces, and their altered expression in cancer leads to tumor progression, metastasis, angiogenesis and stemness through different signalling pathways. Promoter methylation, microRNA, and histone modification constitute the epigenetic changes that regulate galectin activity in cancer. Our review discusses the concept of epigenetics in cancer and how the aforementioned factors i.e., promoter methylation, histone modification, change in miRNAs expression affect the glycomic changes in malignancies.
Identifiants
pubmed: 34652614
doi: 10.1007/s10147-021-02048-x
pii: 10.1007/s10147-021-02048-x
doi:
Substances chimiques
Galectins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
35-44Informations de copyright
© 2021. Japan Society of Clinical Oncology.
Références
Cooper D (2002) Galectinomics: finding themes in complexity. Biochim Biophys Acta BBA Gen Subj 1572(2–3):209–231. https://doi.org/10.1016/S0304-4165(02)00310-0
doi: 10.1016/S0304-4165(02)00310-0
Wan L, Yang R-Y, Liu F-T (2018) Galectin-12 in cellular differentiation, apoptosis and polarization. Int J Mol Sci 19(1):176. https://doi.org/10.3390/ijms19010176
doi: 10.3390/ijms19010176
pmcid: 5796125
Liu F-T, Rabinovich GA (2010) Galectins: regulators of acute and chronic inflammation: galectins and inflammation. Ann N Y Acad Sci 1183(1):158–182. https://doi.org/10.1111/j.1749-6632.2009.05131.x
doi: 10.1111/j.1749-6632.2009.05131.x
pubmed: 20146714
pmcid: 20146714
Vasta GR (2009) Roles of galectins in infection. Nat Rev Microbiol 7(6):424–438. https://doi.org/10.1038/nrmicro2146
doi: 10.1038/nrmicro2146
pubmed: 19444247
pmcid: 3759161
Thijssen VL, Heusschen R, Caers J et al (2015) Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta BBA Rev Cancer 2:235–247. https://doi.org/10.1016/j.bbcan.2015.03.003
doi: 10.1016/j.bbcan.2015.03.003
Vasta GR (2012) Galectins as pattern recognition receptors: structure, function, and evolution. In: Lambris JD, Hajishengallis G (eds) Current topics in innate immunity II. Springer, New York, pp 21–36
doi: 10.1007/978-1-4614-0106-3_2
Bianchet MA, Ahmed H, Vasta GR et al (2000) Soluble beta-galactosyl-binding lectin (galectin) from toad ovary: crystallographic studies of two protein-sugar complexes. Proteins 40(3):378–88. https://doi.org/10.1002/1097-0134(20000815)40:3<378::aid-prot40>3.0.co;2-7
doi: 10.1002/1097-0134(20000815)40:3<378::aid-prot40>3.0.co;2-7
pubmed: 10861929
Egger G, Liang G, Aparicio A et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457–463. https://doi.org/10.1038/nature02625
doi: 10.1038/nature02625
pubmed: 15164071
Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415–428. https://doi.org/10.1038/nrg816
doi: 10.1038/nrg816
pubmed: 12042769
Lauc G, Zoldoš V (2009) Epigenetic regulation of glycosylation could be a mechanism used by complex organisms to compete with microbes on an evolutionary scale. Med Hypotheses 73(4):510–512. https://doi.org/10.1016/j.mehy.2009.03.059
doi: 10.1016/j.mehy.2009.03.059
pubmed: 19560282
Cooper DN (1983) Eukaryotic DNA methylation. Hum Genet 64(4):315–333. https://doi.org/10.1007/BF00292363
doi: 10.1007/BF00292363
pubmed: 6194100
Ohm JE, McGarvey KM, Yu X et al (2007) A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39(2):237–242. https://doi.org/10.1038/ng1972
doi: 10.1038/ng1972
pubmed: 17211412
pmcid: 2744394
Meissner A, Mikkelsen TS, Gu H et al (2008) Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454(7205):766–770. https://doi.org/10.1038/nature07107
doi: 10.1038/nature07107
pubmed: 18600261
pmcid: 2896277
Rodríguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17(3):330–339. https://doi.org/10.1038/nm.2305
doi: 10.1038/nm.2305
pubmed: 21386836
Mashimo M, Kato J, Moss J (2013) ADP-ribosyl-acceptor hydrolase 3 regulates poly (ADP-ribose) degradation and cell death during oxidative stress. Proc Natl Acad Sci 110(47):18964–18969. https://doi.org/10.1073/pnas.1312783110
doi: 10.1073/pnas.1312783110
pubmed: 24191052
pmcid: 3839768
Pasquinelli AE (2012) MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 13(4):271–282. https://doi.org/10.1038/nrg3162
doi: 10.1038/nrg3162
pubmed: 22411466
Sun W, Liu Y, Glazer CA et al (2010) TKTL1 Is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1 stabilization. Clin Cancer Res 16(3):857–866. https://doi.org/10.1158/1078-0432.CCR-09-2604
doi: 10.1158/1078-0432.CCR-09-2604
pubmed: 20103683
pmcid: 2824550
Barbano R, Muscarella LA, Pasculli B et al (2013) Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 8(1):105–112. https://doi.org/10.4161/epi.23319
doi: 10.4161/epi.23319
pubmed: 23249627
pmcid: 3549873
Chao C, Chi M, Preciado M et al (2013) Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control 24(9):1615–1641. https://doi.org/10.1007/s10552-013-0249-2
doi: 10.1007/s10552-013-0249-2
pubmed: 23797237
Mehta A, Dobersch S, Romero-Olmedo AJ et al (2015) Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev 34(2):229–241. https://doi.org/10.1007/s10555-015-9563-3
doi: 10.1007/s10555-015-9563-3
pubmed: 25939322
Liu X, Brenner DA (2016) DNA methylation controls liver fibrogenesis. Nat Rev Gastroenterol Hepatol 13(3):126–128. https://doi.org/10.1038/nrgastro.2016.16
doi: 10.1038/nrgastro.2016.16
pubmed: 26860269
Cecotka A, Polanska J (2018) Region-specific methylation profiling in acute myeloid leukemia. Interdiscip Sci Comput Life Sci 10(1):33–42. https://doi.org/10.1007/s12539-018-0285-4
doi: 10.1007/s12539-018-0285-4
Klughammer J, Kiesel B, Roetzer T et al (2018) The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med 24(10):1611–1624. https://doi.org/10.1038/s41591-018-0156-x
doi: 10.1038/s41591-018-0156-x
pubmed: 30150718
pmcid: 6181207
Satelli A, Rao US (2011) Galectin-1 is silenced by promoter hypermethylation and its re-expression induces apoptosis in human colorectal cancer cells. Cancer Lett 301(1):38–46. https://doi.org/10.1016/j.canlet.2010.10.027
doi: 10.1016/j.canlet.2010.10.027
pubmed: 21122983
Krawczyk J, Keane N, Freeman CL et al (2013) 5-Azacytidine for the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 14(9):1255–1268. https://doi.org/10.1517/14656566.2013.794222
doi: 10.1517/14656566.2013.794222
pubmed: 23621771
Ahmed H, Banerjee PP, Vasta GR (2007) Differential expression of galectins in normal, benign and malignant prostate epithelial cells: Silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 358(1):241–246. https://doi.org/10.1016/j.bbrc.2007.04.114
doi: 10.1016/j.bbrc.2007.04.114
pubmed: 17481580
Ahmed H, Cappello F, Rodolico V et al (2009) Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol 2(3):146–156. https://doi.org/10.1593/tlo.09118
doi: 10.1593/tlo.09118
pubmed: 19701499
pmcid: 2730137
Keller S, Angrisano T, Florio E et al (2013) DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. Oncol Lett 6(1):86–90. https://doi.org/10.3892/ol.2013.1312
doi: 10.3892/ol.2013.1312
pubmed: 23946782
pmcid: 3742793
Demers M, Couillard J, Giglia-Mari G et al (2009) Increased galectin-7 gene expression in lymphoma cells is under the control of DNA methylation. Biochem Biophys Res Commun 387(3):425–429. https://doi.org/10.1016/j.bbrc.2009.07.015
doi: 10.1016/j.bbrc.2009.07.015
pubmed: 19596268
Kim S-J, Hwang J-A, Ro JY et al (2013) Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 4(9):1461–1471. https://doi.org/10.18632/oncotarget.1219
Jung G, Hernández-Illán E, Moreira L et al (2020) Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol 17(2):111–130. https://doi.org/10.1038/s41575-019-0230-y
doi: 10.1038/s41575-019-0230-y
pubmed: 31900466
pmcid: 7228650
Fraga MF, Ballestar E, Villar-Garea A et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37(4):391–400. https://doi.org/10.1038/ng1531
doi: 10.1038/ng1531
pubmed: 15765097
Moreno DA, Scrideli CA, Cortez MAA et al (2010) Research paper: differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia: HDAC Expression in Paediatric ALL. Br J Haematol 150(6):665–673. https://doi.org/10.1111/j.1365-2141.2010.08301.x
doi: 10.1111/j.1365-2141.2010.08301.x
pubmed: 20636436
Tao Y-F, Pang L, Du X-J et al (2013) Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia. Int J Mol Sci 14(2):3376–3394. https://doi.org/10.3390/ijms14023376
doi: 10.3390/ijms14023376
pubmed: 23389039
pmcid: 3588049
Choi J-H, Kwon HJ, Yoon B-I et al (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92(12):1300–1304. https://doi.org/10.1111/j.1349-7006.2001.tb02153.x
doi: 10.1111/j.1349-7006.2001.tb02153.x
pubmed: 11749695
pmcid: 5926683
Halkidou K, Gaughan L, Cook S et al (2004) Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer. Prostate 59(2):177–189. https://doi.org/10.1002/pros.20022
doi: 10.1002/pros.20022
pubmed: 15042618
Wilson AJ, Byun D-S, Popova N et al (2006) Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer. J Biol Chem 281(19):13548–13558. https://doi.org/10.1074/jbc.M510023200
doi: 10.1074/jbc.M510023200
pubmed: 16533812
Zhang Z, Yamashita H, Toyama T et al (2005) Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*. Breast Cancer Res Treat 94(1):11–16. https://doi.org/10.1007/s10549-005-6001-1
doi: 10.1007/s10549-005-6001-1
pubmed: 16172792
Armenta-Castro E, Reyes-Vallejo T, Máximo-Sánchez D et al (2020) Histone H3K9 and H3K14 acetylation at the promoter of the LGALS9 gene is associated with mRNA levels in cervical cancer cells. FEBS Open Bio 10(11):2305–2315. https://doi.org/10.1002/2211-5463.12973
doi: 10.1002/2211-5463.12973
pubmed: 32902187
pmcid: 7609790
Garzon R, Calin GA, Croce CM (2009) MicroRNAs in cancer. Annu Rev Med 60(1):167–179. https://doi.org/10.1146/annurev.med.59.053006.104707
doi: 10.1146/annurev.med.59.053006.104707
pubmed: 19630570
He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522–531. https://doi.org/10.1038/nrg1379
doi: 10.1038/nrg1379
pubmed: 15211354
pmcid: 15211354
Bruce JP, Hui ABY, Shi W, et al (2015) Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. Oncotarget 6(6):4537–4550. https://doi.org/10.18632/oncotarget.3005
Deng S, Calin GA, Croce CM et al (2008) Mechanisms of microRNA deregulation in human cancer. Cell Cycle 7(17):2643–2646. https://doi.org/10.4161/cc.7.17.6597
doi: 10.4161/cc.7.17.6597
pubmed: 18719391
Valoczi A (2004) Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res 32(22):e175–e175. https://doi.org/10.1093/nar/gnh171
doi: 10.1093/nar/gnh171
pubmed: 15598818
pmcid: 545470
Takahashi R, Prieto-Vila M, Kohama I et al (2019) Development of miRNA-based therapeutic approaches for cancer patients. Cancer Sci 110(4):1140–1147. https://doi.org/10.1111/cas.13965
doi: 10.1111/cas.13965
pubmed: 30729639
pmcid: 6447849
Baer C, Squadrito ML, Laoui D et al (2016) Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity. Nat Cell Biol 18(7):790–802. https://doi.org/10.1038/ncb3371
doi: 10.1038/ncb3371
Lu W, Wang J, Yang G, et al (2017) Posttranscriptional regulation of Galectin-3 by miR-128 contributes to colorectal cancer progression. Oncotarget 8(9):15242–15251. https://doi.org/10.18632/oncotarget.14839
Ramasamy S, Duraisamy S, Barbashov S et al (2007) The MUC1 and Galectin-3 Oncoproteins Function in a MicroRNA-Dependent Regulatory Loop. Mol Cell 27(6):992–1004. https://doi.org/10.1016/j.molcel.2007.07.031
doi: 10.1016/j.molcel.2007.07.031
pubmed: 17889671
pmcid: 4217170
Yang Q, Hou C, Huang D et al (2017) miR-455-5p functions as a potential oncogene by targeting galectin-9 in colon cancer. Oncol Lett 13(3):1958–1964. https://doi.org/10.3892/ol.2017.5608
doi: 10.3892/ol.2017.5608
pubmed: 28454350
pmcid: 5403439
Kang HG, Kim D-H, Kim S-J, et al (2016) Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget 7(42):68229–68241. https://doi.org/10.18632/oncotarget.11920
Bieg D, Sypniewski D, Nowak E et al (2019) MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet 299(4):1077–1087. https://doi.org/10.1007/s00404-018-4999-7
doi: 10.1007/s00404-018-4999-7
pubmed: 30585294
Zhang J, Zhao X, Zhang J et al (2018) Circular RNA hsa_circ_0023404 exerts an oncogenic role in cervical cancer through regulating miR-136/TFCP2/YAP pathway. Biochem Biophys Res Commun 501(2):428–433. https://doi.org/10.1016/j.bbrc.2018.05.006
doi: 10.1016/j.bbrc.2018.05.006
pubmed: 29738762
Meng S, Zhou H, Feng Z et al (2017) CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer 16(1):94. https://doi.org/10.1186/s12943-017-0663-2
doi: 10.1186/s12943-017-0663-2
pubmed: 28535767
pmcid: 5440908
Hansen TB, Jensen TI, Clausen BH et al (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495(7441):384–388. https://doi.org/10.1038/nature11993
doi: 10.1038/nature11993
pubmed: 23446346
pmcid: 23446346
Qiu B, Zhang P, Xiong D et al (2019) CircRNA fibroblast growth factor receptor 3 promotes tumor progression in non-small cell lung cancer by regulating Galectin-1-AKT/ERK1/2 signaling. J Cell Physiol 234(7):11256–11264. https://doi.org/10.1002/jcp.27783
doi: 10.1002/jcp.27783
pubmed: 30565694
Sun X, Cui M, Zhang A et al (2016) MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist. J Exp Clin Cancer Res 35(1):10. https://doi.org/10.1186/s13046-016-0288-0
doi: 10.1186/s13046-016-0288-0
pubmed: 26762267
pmcid: 4712560
Chen X, Chen Y, Hu Q et al (2018) MiR-548c inhibits lung cancer cell proliferation through suppression of Galectin-3-mediated TLR4 signaling pathway. Int J Clin Exp Med 11(2):581–592
Yang Q, Jiang W, Zhuang C et al (2015) microRNA-22 downregulation of galectin-9 influences lymphocyte apoptosis and tumor cell proliferation in liver cancer. Oncol Rep 34(4):1771–1778. https://doi.org/10.3892/or.2015.4167
doi: 10.3892/or.2015.4167
pubmed: 26239725
Tadokoro T, Fujihara S, Chiyo T et al (2017) Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: in vitro study. Int J Oncol 51(2):607–614. https://doi.org/10.3892/ijo.2017.4053
doi: 10.3892/ijo.2017.4053
pubmed: 28656219
Wu H, Song S, Yan A et al (2020) RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1. Cancer Lett 469:287–300. https://doi.org/10.1016/j.canlet.2019.11.002
doi: 10.1016/j.canlet.2019.11.002
pubmed: 31705928